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Abstract 
Background: Mitochondrial dysfunction is observed in various neuropathic pain phenotypes, such as chemotherapy 
induced neuropathy, diabetic neuropathy, HIV-associated neuropathy, and in Charcot-Marie-Tooth neuropathy. To 
investigate whether mitochondrial dysfunction is present in trauma-induced painful mononeuropathy, a time-course 
of mitochondrial function and bioenergetics was characterized in the mouse partial sciatic nerve ligation model.
Results: Traumatic nerve injury induces increased metabolic indices of the nerve, resulting in increased oxygen 
consumption and increased glycolysis. Increased metabolic needs of the nerve are concomitant with bioenergetic 
and mitochondrial dysfunction. Mitochondrial dysfunction is characterized by reduced ATP synthase activity, reduced 
electron transport chain activity, and increased futile proton cycling. Bioenergetic dysfunction is characterized by 
reduced glycolytic reserve, reduced glycolytic capacity, and increased non-glycolytic acidification.
Conclusion: Traumatic peripheral nerve injury induces persistent mitochondrial and bioenergetic dysfunction which 
implies that pharmacological agents which seek to normalize mitochondrial and bioenergetic dysfunction could be 
expected to be beneficial for pain treatment. Increases in both glycolytic acidification and non-glycolytic acidifica-
tion suggest that pH sensitive drugs which preferentially act on acidic tissue will have the ability to preferential act on 
injured nerves without affecting healthy tissues.
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Background
There is accumulating evidence that mitochondrial dysfunc-
tion plays a role in conditions of painful peripheral neuropa-
thy [1, 2]. For example, mitochondrial dysfunction has been 
observed in models of chemotherapy induced neuropathy 
[3], diabetic neuropathy [4], and in HIV-associated sen-
sory neuropathy [5]. Furthermore, in humans, mutations in 
mitochondrial genes frequently result in the development 
of painful peripheral neuropathy, as seen in patients with 
Charcot-Marie-Tooth disease [6]. Clearly, mitochondria are 
mechanistically involved in neuropathic pain, and a further 
understanding and characterization of the role that mito-
chondria play in pain pathogenesis is required.
Under normal physiological conditions, mitochondria 
are responsible for the production of the majority of ATP 
in neurons [7]. Mitochondria produce ATP by oxidation 
of pyruvate through the oxidative phosphorylation res-
piratory chain complex. Under conditions of mitochon-
drial dysfunction, a lack of ATP can lead to a failure in 
the Na+/K+ ATPase, and in primary sensory neurons this 
may contribute to ectopic activity characteristic of neu-
ropathic pain [8]. Mitochondria also have roles in the 
production and modulation of reactive oxygen species 
(ROS) [9], as well as in the maintenance of cytosolic Ca2+ 
levels [10]. Mitochondrial dysfunction leads to increased 
ROS and cytosolic Ca2+ imbalances—mechanisms which 
have both been previously implicated in neuropathic 
pain pathogenesis [11, 12]. Furthermore, a lack of ATP 
shifts cellular ATP production to glycolysis [13], which 
can result in lactate acidosis. Tissue acidosis is well 
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recognized mechanism that can cause constant ongoing 
pain [14].
While there is mounting evidence to suggest that 
dysfunctional mitochondria play a role in periph-
eral neuropathy, whether mitochondrial dysfunction 
in peripheral tissue contributes to pain pathogenesis 
in trauma-induced peripheral mononeuropathy is not 
known. Furthermore, our knowledge of the role that cel-
lular bioenergetics play in neuropathic pain is unknown. 
The goal of this manuscript was to fill this knowledge 
gap by characterizing the time course and chronicity of 
mitochondrial and bioenergetic dysfunction in a model 
of painful trauma-induced peripheral neuropathy. Par-
tial sciatic nerve ligation (PSNL) decreases the paw 
withdrawal thresholds shortly after the surgery and this 
mechanical hypersensitivity persists for at least 1 month 
[15]. This work demonstrates that traumatic peripheral 
nerve injury, e.g., PSNL, induces persistent mitochon-
drial and bioenergetic dysfunction, and suggests that 
these mechanisms contribute to pain pathogenesis and 
can be exploited to develop pharmaceutical agents which 
act preferentially at injured nerves.
Results
The bioenergetic profile of mouse sciatic nerves can be 
measured using metabolic poisons
A method to examine the bioenergetics profile of mice 
nerves was developed. Oxygen consumption and extra-
cellular acidification rates from mouse sciatic nerves 
ex  vivo were measured with the Seahorse XF extracel-
lular flux analyzer. Oligomycin, FCCP, and antimycin A 
with rotenone was used to measure oxygen consumption 
linked to: total respiration, ATP-linked respiration, pro-
ton leak, non-mitochondrial respiration, maximal mito-
chondrial respiration, and the spare respiratory capacity 
(Fig.  1a). Oligomycin and 2-deoxy-d-glucose were used 
to measure extracellular acidification linked to: glycoly-
sis, non-glycolygic acidification, glycolytic capacity, and 
glycolytic reserve (Fig. 1b).
Nerve injury causes a persistent increase in total oxygen 
consumption and extracellular acid production
Following partial sciatic nerve ligation, as soon as 1 day 
post-surgery, total oxygen consumption levels of nerves 
were persistently increased (Fig. 2a). In a similar manner, 
mitochondrial respiration of nerves was also increased 
post-injury (Fig. 2b). Nerve injury persistently increased 
total extracellular rates of acidification as soon as 1 day 
post-injury (Fig.  2c). Glycolysis specific extracellular 
acidification was significantly increased as well (Fig. 2d).
Mitochondria in injured nerves have reduced ATP‑linked 
respiration, spare capacity, maximal mitochondrial 
respiration, and increased proton leak
Oligomycin inhibits ATP synthase by blocking the pro-
ton channel subunit F0. Thus, by adding oligomycin to 
the nerves, the respiration specific to ATP synthesis can 
be measured. Following nerve injury, oxygen consump-
tion linked to ATP production decreased, and was sig-
nificantly reduced by day 7 post-injury, until at least day 
28 post-injury (Fig. 3a). FCCP is a mitochondrial uncou-
pling agent which discharges the pH gradient across the 
inner mitochondrial membrane. This induces the mito-
chondria to work at their maximum respiratory rate, 
Fig. 1 The bioenergetic profile of mouse sciatic nerves can be assessed by Seahorse metabolic assay. Sciatic nerves from mice were isolated and 
cut into small 1 mm hemi-segments. Tissue from a 3 mm long segment of nerve was placed into a single well. a Oxygen consumption rate was 
measured, and the oxygen consumption rate in response to oligomycin, FCCP, and antimycin A with rotenone was determined. This allowed ex vivo 
measurement of oxygen consumption specific to total cellular respiration, mitochondrial respiration, mitochondrial ATP production, mitochondrial 
proton leak, mitochondrial maximal respiration, mitochondrial spare respiratory capacity, and non-mitochondrial respiration. b Extracellular acidi-
fication rate can also be measured by this method. Ex vivo measurement of the extracellular acidification rate corresponding to total extracellular 
acidification, glycolysis, glycolytic capacity, glycolytic reserve, and non-glycolytic acidification can be measured following administration of oligomy-
cin and 2-deoxyglucose to the tissue culture medium
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allowing measurement of mitochondrial spare capacity 
and maximum mitochondrial respiration. By day 7 post-
injury, mitochondria in injured nerves have significantly 
reduced spare capacity—at levels near zero (Fig.  3b). 
Spare capacity is significantly reduced until at least day 
28, suggesting persistent effects of nerve injury on mito-
chondria. Not only is the spare capacity reduced by nerve 
injury, maximal mitochondrial respiration is also signifi-
cantly reduced after day 7 post-injury (Fig. 3c). Rotenone 
and antimycin A are inhibitors of the electron trans-
port chain at complex I and III, respectively. Subtract-
ing oxygen consumption after oligomycin from oxygen 
consumption after antimycin A and rotenone administra-
tion gives the mitochondrial oxygen consumption that is 
unrelated to ATP synthesis, or proton leak. Proton leak is 
significantly increased after day 7 to at least day 28 post-
injury (Fig. 3d).
Injured nerves have reduced glycolytic reserve 
and glycolytic capacities
The glycolytic reserve is a measure of the ability of the tis-
sue to increase glycolytic flux to respond to an enhanced 
need for ATP by glycolytic flux. This can be measured 
by introducing oligomycin to the tissue. The glycolytic 
reserve was significantly decreased after nerve injury, as 
early as day 1 post-injury, and persisted until at least day 
28 post-injury (Fig. 4a). Glycolytic capacity measures the 
entire ability of the tissue to produce ATP by glycolysis. 
Glycolytic capacity was measured and it was also simi-
larly significantly reduced in a persistent manner as early 
as day 1 post-injury (Fig. 4b).
Nerve injury does not affect non‑mitochondrial 
respiration, but increases non‑glycolytic acidification
Non-mitochondrial respiration was measured with the 
addition of antimycin A and rotenone to the tissue. No 
significant changes in non-mitochondrial respiration 
were observed after nerve injury (Fig.  5a). In a simi-
lar fashion, non-glycolytic acidification can be meas-
ured by administering 2-deoxy-d-glucose to the tissue 
which inhibits glycolysis. Interestingly, non-glycolytic 
acidification was increased as early as 1 day after nerve 
injury, and the increase persisted until at least day 28 
(Fig. 5b).
Fig. 2 Partial sciatic nerve ligation causes persistently increased metabolic needs of injured nerves. a Total cellular oxygen consumption is per-
sistently increased following nerve injury. This demonstrates that under ex vivo conditionsf b The oxygen consumption specific to mitochondrial 
respiration is also persistently increased following nerve injury. c Total extracellular acidification levels are persistently increased following nerve 
injury, demonstrating that injured nerves produce more acid than uninjured nerves. d Glycolysis specific extracellular acidification is also increased
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Fig. 3 Partial sciatic nerve ligation induces persistent mitochondrial dysfunction in injured nerves. a The proportion of the oxygen consumption 
rate specific to mitochondrial ATP production is persistently reduced following partial sciatic nerve ligation, demonstrating dysfunction in mito-
chondrial ATP production. b Additionally, the mitochondria of injured nerves have no spare capacity. When stimulated pharmacologically with a 
proton uncoupling agent, mitochondria are unable to consume any more oxygen after nerve injury. This suggests that the mitochondria in injured 
nerves are under bioenergetic stress and are already operating at their maximum capabilities for ATP production. c Maximal mitochondrial respira-
tion is persistently reduced following nerve injury. This demonstrates that nerve injury reduces the ability of mitochondria to perform oxidative 
processes. d Futile proton cycling, or proton leak, is increased in mitochondria following nerve injury. Mitochondria undergo changes to allow more 
protons to passively dissipate the proton motive force after nerve injury. This avails fewer protons for ATP synthesis
Fig. 4 Partial sciatic nerve ligation induces persistent glycolytic dysfunction in injured nerves. a The proportion of the extracellular acidification rate 
specific to glycolysis is persistently reduced following partial sciatic nerve ligation. This demonstrates that the ability of the nerve to increase gly-
colytic activity in response to bioenergic stress is reduced following nerve injury. b Glycolytic capacity is also persistently reduced following partial 
sciatic nerve ligation. A reduction in glycolytic capacity suggests injured nerve tissue is less capable of producing ATP by glycolytic mechanisms
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Discussion
Traumatic injury causing painful mononeuropathy 
increases the metabolic needs of the nerve
Following nerve injury, large numbers of immune cells 
enter into the nerve to contribute to neuroinflamma-
tion, Wallerian degeneration and neuropathic pain [15, 
16]. An approximate 3-fold increase in the number of 
DAPI nucleated cells is observed [8], which agrees with 
the 3-fold increase in total oxygen consumption levels 
seen in Fig. 2a. Mitochondrial specific respiration is also 
increased (Fig. 2b), suggesting that increased oxygen con-
sumption by mitochondria underlie at least a part of the 
increase in total oxygen consumption following nerve 
injury.
Similarly, Fig. 2c shows a marked increase in total extra-
cellular acidification rates following nerve injury. Likely, 
one of the factors that explains the increased extracellular 
acidification rate is the increased number of cells within 
injured nerves, which results in increased lactic acidosis 
[8]. Indeed, extracellular acidification rates which can be 
attributed to glycolysis is significantly increased, as seen 
in Fig.  2d. This demonstrates that at least some of the 
increase in total acidification rates following nerve injury 
can be attributed to increased glycolysis.
ATP synthase activity is repressed by traumatic nerve 
injury causing painful mononeuropathy
Under physiological conditions, mitochondria produce 
ATP through the oxidation of glucose metabolites, such 
as pyruvate and NADH. This is performed by the F0F1 
ATP synthase which resides on the inner mitochondrial 
membrane. Oligomycin is an inhibitor of ATP synthase 
and applying it to nerve tissue allows the measurement 
of ATP synthase activity. Interestingly, while mitochon-
drial specific oxygen consumption increased as described 
above, the proportion of oxygen consumption specific to 
ATP synthase activity is reduced by nerve injury (Fig. 3a).
Hypoxia is present in injured nerves [8], and likely 
contributes to the inhibition of ATP synthase. A lack of 
oxygen slows oxidative phosphorylation, decreasing the 
mitochondrial membrane potential and causes the F0F1 
ATP synthase to run in reverse, resulting in a dissipation 
of ATP [17]. To avoid this potentially disastrous situation, 
the F0F1 ATP synthase is regulated by the protein IF1, 
which reversibly inhibits the F0F1 ATP synthase under 
conditions of low pH and low mitochondrial membrane 
potentials, which occur during hypoxia. This mechanism 
likely explains why nerve injury reduces oxygen con-
sumption attributable to ATP synthase.
Traumatic nerve injury causing painful mononeuropathy 
induces severe bioenergetic stress on mitochondria
Spare respiratory capacity measures the ability of the tis-
sue to respond to an increased ATP demand or increased 
workload. A failure of the mitochondria to meet ATP 
demands under metabolically stressful conditions can 
result in cell death [18] and neurodegeneration [19, 20]. 
After nerve injury, a reduction in the spare respiratory 
capacity is observed, with mitochondria in injured nerves 
operating with no spare capacity (Fig.  3b). Thus, trau-
matic nerve injury induces a profound oxidative stress 
on the injured tissue, and the nerve has little to no ability 
to increase mitochondrial activity to respond to further 
metabolic distress.
Traumatic nerve injury causing painful mononeuropathy 
negatively affects the ability of mitochondria to perform 
oxidative phosphorylation
The maximal respiratory capacity is a measure of both 
the ability of a cell to supply substrates to mitochondria, 
Fig. 5 Nerve injury does not affect non-mitochondrial respiration, but increases non-glycolytic acidification. a Nerve injury induces no proportion-
ate change in non-mitochondrial respiration. This suggests that oxygen consumption of non-mitochondrial processes such as cellular oxidases 
do not undergo alterations following nerve injury. b Nerve injury induces a persistent increase in non-glycolytic acidification. This suggests that 
non-glycolytic processes which produce acids are increased following nerve injury. Increased acidification may have undesirable effects on sensory 
neuron excitability
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as well as the ability of the mitochondria to oxidize 
the substrates. Hypoxia is in fact a regulator of oxida-
tive phosphorylation machinery at a number of loca-
tions and can explain the reduced maximal respiratory 
capacity after nerve injury. Hypoxia inducible factor-1 
(HIF-1) induces pyruvate dehydrogenase kinase, which 
in turn inhibits pyruvate dehydrogenase, limiting the 
amount of pyruvate available for oxidative phosphoryla-
tion [21]. Furthermore, hypoxia regulates complex IV of 
the electron transport chain, also known as cytochrome 
C oxidase (COX), and reduces the maximal rate of COX 
activity [22, 23]. Thus, hypoxia—which is present after 
nerve injury—reduces both the ability of the cell and 
mitochondria to carry out oxidative phosphorylation, 
which will decrease the maximal respiratory capacity of 
injured nerves (Fig. 3c).
Traumatic injury causing painful mononeuropathy causes 
mitochondria to increase futile proton cycling, further 
contributing to mitochondrial dysfunction
As an alternative to ATP generation, the protonmotive 
force generated by the electron transport chain can also 
be consumed by leaking back across the inner mitochon-
drial membrane. Studies in rat have found that proton 
leak contributes to approximately 25 % of the resting res-
piratory rate [24], a value similar to the resting proton 
leak in mouse sciatic nerve which was determined to be 
approximately 28 % (Fig. 3d). After nerve injury, proton 
leak increases to approximately 45 % of the total respira-
tory rate. Thus, after nerve injury, more of the proton 
motive force generated by mitochondria is dissipated, 
resulting in even less ATP generated by mitochondria.
Furthermore, mitochondria regulate and increase pro-
ton leak in order to and reduce ROS generation [25]. 
Previously, it has been demonstrated that nerve injury 
induces ongoing and persistent vascular dysfunction, 
resulting in ischemia and hypoxia [8]. It is well known 
that mitochondria in ischemic tissue generate reactive 
oxygen species (ROS) [26]. Indeed, the role of increased 
ROS is well characterized in neuropathic pain [11]. 
The observation that proton leak increased after nerve 
injury, is likely due to mitochondria responding to an 
increased presence of ROS and upregulating proton leak 
in response.
Reduced glycolytic reserve and capacity demonstrates 
persistent bioenergetic deficit after traumatic injury 
causing painful mononeuropathy
The glycolytic reserve provides a measure of the ability of 
the tissue to accommodate increased ATP needs. Follow-
ing nerve injury, injured nerve has a reduced glycolytic 
reserve (Fig. 4a), suggesting that the tissue is under bio-
energetic stress and has little ability to accommodate an 
increase in ATP demand. Further evidence of impaired 
glycolysis is the observation of a reduction in glycolytic 
capacity (Fig.  4b). Normally, after exposure to bioen-
ergetic stressors such as hypoxia, cells can respond by 
increasing glycolysis related enzymes through HIF-1 
[21, 27]. This leads to the Warburg effect, whereby cells 
switch their metabolic pathways, favoring glycolysis over 
oxidative phosphorylation [28]. However, while an over-
all increase in glycolysis is observed after nerve injury, 
glycolytic mechanisms appear to be dysfunctional. Likely, 
a persistent oxygen and glucose deficit due to vascular 
dysfunction induces ATP conservation mechanisms [29, 
30]. This metabolic suppression may have functional 
implications on pain, resulting in a decrease in the Na+/
K+ ATPase and increased nociceptor excitability [8].
Mitochondria are the major source of reactive oxygen 
species following traumatic nerve injury causing painful 
mononeuropathy
While most oxygen is consumed by cells in pathways 
which involve oxidative phosphorylation, oxygen can also 
be consumed by non-mitochondrial activities. Examples 
of these processes include the NOX family of NADPH 
oxidases [31], and xanthine oxidases [32]. Both of these 
enzymes are involved in producing cellular ROS and are 
not involved in mitochondrial respiration. The lack of 
any substantial change in non-mitochondrial respira-
tion from injured nerves (Fig. 5a) demonstrates that the 
source of the majority of ROS after nerve injury is the 
mitochondria themselves.
Non‑glycolytic pathways are a major source of protons 
following traumatic nerve injury causing painful 
mononeuropathy
Non-glycolytic acidosis is persistently increased by nerve 
injury (Fig.  5b). After nerve injury the tissue produces 
acid though mechanisms which are not involved with 
ATP synthesis. Enhanced tissue acidification has been 
described in conditions of chronic inflammation, such 
as asthma [33], rheumatoid arthritis [34], and arthroscle-
rosis [35]. These results, in conjunction with the results 
demonstrating increased glycolysis following nerve 
injury, suggest that bioenergetic dysfunction following 
nerve injury induces chronic acidosis of the nerve. The 
presence of proton sensing ion channels such as TRPV1 
and ASICs in sensory neurons has been verified numer-
ous times in the past [36–39], but whether or not these 
ion channels contribute to pain pathogenesis in neuro-
pathic conditions is unclear, as little evidence of acido-
sis after nerve injury has been previously demonstrated. 
However, the results here establish that increased proton 
production by both glycolysis and non-glycolytic path-
ways occur, as early as 1 day after nerve trauma.
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Bioenergetic and mitochondrial dysfunction contribute 
to neuropathic pain pathophysiology
A deficit in cellular ATP is expected to result in a reduc-
tion in the activity of the Na+/K+ ATPase, which will 
elevate the resting membrane potential and lead to 
spontaneous activity of sensory neurons [1]. Further-
more, a reduction in cellular ATP levels should simu-
late increased glycolysis, which can result in metabolic 
acidosis, and activation of proton sensitive ion channels 
such as TRPV1 and ASICs. After nerve injury, resident 
and infiltrating macrophages activate and polarize to the 
M1 pro-inflammatory phenotype [40]. Excessive immune 
responses by M1 macrophages can be detrimental to 
the host [41] and are neurotoxic [42]. M1 macrophages 
mostly obtain their energy through anaerobic glycolysis 
[43, 44], and the presence of these macrophages likely 
also accounts for the increased glycolysis observed after 
nerve injury.
Implications for future pharmacotherapy of neuropathic 
pain
Altering the metabolic programming of macrophages can 
alter their phenotype. For example, blocking oxidative 
metabolism polarizes macrophages to the M1 phenotype 
[45]. M1 polarized macrophages produce ROS, secrete 
pro-inflammatory cytokines and chemokines, contribute 
to lactate acidosis, and cause tissue damage [46]. Con-
versely, forcing oxidative metabolism in M1 macrophages 
polarizes the macrophage to the anti-inflammatory tissue 
repair M2 phenotype [45]. Thus, pharmacological agents 
which inhibit glycolytic metabolism in macrophages are 
expected to produce beneficial effects on pain by attenu-
ating the harmful M1 macrophage phenotype.
Following traumatic nerve injury, vascular dysfunc-
tion leads to persistent hypoxia of the nerve [8]. The 
lack of oxygen leads to mitochondrial dysfunction, and 
an energy deficit within the nerve. This energy defi-
cit will lead to a reduction in the activity of the Na+/K+ 
ATPase, which will elevate the resting membrane poten-
tial and lead to spontaneous activity of sensory neurons 
[1]. Drugs which protect mitochondria from dysfunction 
are expected to have beneficial effects following trau-
matic nerve injury. For example, previous reports have 
described efficacy of mitoprotective drugs such as acetyl-
l-carnitine in the chronic constriction injury model of 
painful traumatic neuropathic pain [47]. Our work pro-
vides a clear mechanism how mitochondrial protection is 
beneficial for trauma-induced neuropathic pain.
In addition, our study demonstrates that after nerve 
injury, bioenergetic dysfunction induces persistent aci-
dosis of the nerve. This persistent acidified state pro-
vides the rationale for the creation of drugs which have 
increased potency under acidic conditions, such as those 
which have been created for cardiac arrhythmia [48]. An 
ion channel type blocking drug which is more active at 
acidic conditions will have enhanced therapeutic ratios, 
as the drug would preferentially affect injured nerves 
without affecting healthy nervous tissue.
Conclusions
Traumatic nerve injury induces increased oxygen con-
sumption and glycolysis, resulting in hypoxia and aci-
dosis. Increased metabolic needs of the nerve are 
concomitant with bioenergetic and mitochondrial dys-
function. Mitochondrial dysfunction is characterized 
by repression of ATP synthase, reduced activity of elec-
tron transport chain activity and increased futile proton 
cycling. Bioenergetic dysfunction is characterized by 
reduced glycolytic reserve, reduced glycolytic capacity, 
and increased non-glycolytic acidification. Pharmacolog-
ical agents which seek to normalize mitochondrial and 
bioenergetic dysfunction are expected to be beneficial for 
pain treatment. Increases in both glycolytic acidification 
and non-glycolytic acidification suggest drugs that pref-
erentially act on acidic tissue may have preferential activ-
ity at injured nerves without affecting healthy tissues.
Materials and methods
Animals
Experiments were carried out in adult C57BL/6 mice 
(male, 20–25 g in weight) purchased from Charles River 
Laboratories (Quebec, Canada). Mice were housed four 
to five per cage, in a temperature- and humidity-con-
trolled vivarium, on a 12/12 h light/dark cycle beginning 
at 7:00 AM, with access to rodent chow and water ad libi-
tum. All experiments were approved by the Institutional 
Animal Care and Use Committee of McGill University 
(Permit #5775) and conformed to the ethical guidelines 
of the International Association for the Study of Pain.
Drugs and materials
Oligomycin A, Carbonyl cyanide 4-(trifluoromethoxy)
phenylhydrazone (FCCP), rotenone, antimycin A, and 
2-deoxy-d-glucose were purchased from Sigma-Aldrich. 
Oligomycin A and FCCP were dissolved in ethanol, anti-
mycin A and rotenone were dissolved in DMSO before 
dilution. 2-deoxy-d-glucose was dissolved in supple-
mented XF base media and re-buffered to pH 7.4.
Nerve injury model
Partial sciatic nerve ligation (PSNL) was performed 
according to the method of Seltzer et al. [49], adapted to 
mice [50]. Nerve injury according to this model induces 
a symptoms modeling neuropathic pain in humans, 
including persistent mechanical allodynia. Briefly, mice 
were anesthetized with isoflurane (3  % for induction 
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and maintenance; Baxter Corperation) and under asep-
tic conditions the left sciatic nerve was exposed at high-
thigh level. The dorsum of the nerve was carefully freed 
from surrounding connective tissues at a site near the 
trochanter just distal to the point at which the posterior 
biceps semitendinosus nerve branches off the common 
sciatic nerve. An 8–0 silk suture was inserted into the 
nerve with a 3/8 curved, reversed-cutting mini-needle, 
and tightly ligated so that the dorsal 1/3–1/2 of the nerve 
thickness was trapped in the ligature. The wound was 
then closed with two to three skin sutures (4–0).
Seahorse XF extracellular flux analyzer
At 1, 7, 14, and 28  days post-PSNL injury, mice were 
sacrificed by isoflurane overdose and cervical disloca-
tion. Approximately 1.5 cm long lengths of sciatic nerves 
were immediately extracted and placed in ice cold XF 
base medium minimal DMEM at pH 7.4, supplemented 
with 5.5  mM glucose (Sigma-Aldrich), 0.5  mM sodium 
pyruvate (Invitrogen) and 1  mm glutaMAX (Invitro-
gen). Nerves were cut into three 3  mm segments using 
an acrylic V-shaped 1.0  mm slicer matrix (Zivic Instru-
ments). Nerve segments were then cut in half longi-
tudinally with a razor blade, and then further cut again 
along the cross-sectional axis twice to create 1 mm long 
hemi-sections. The pieces of a 3 mm long length of sci-
atic nerve were transferred into a single well of a XF96 
cell culture microplate (Seahorse Bioscience), with 140 µl 
of cold supplemented XF base medium. Each nerve was 
tested in triplicate, with each 3  mm section making up 
one single triplicate. Various time points after nerve 
injury were tested, including contralateral (n = 27), ipsi 
day 1 (n =  5), ipsi day 7 (n =  12), ipsi day 14 (n =  5), 
and ipsi day 28 (n = 7). Oxygen consumption rates and 
extracellular acidification rates were measured with an 
XF 96 Analyzer (Seahorse Bioscience). An assay cycle of 
2 min mix, 2 min wait, and 3 min measure protocol was 
repeated four times for baseline rates, and three times 
after each injection port. Injection ports contained: oli-
gomycin A (20 µl, 12.5 µM), FCCP (20 µl, 12.5 µM), rote-
none with antimycin A (20 µl total, both drugs 12.5 µM), 
and 2-deoxy-d-glucose (20 µl, 1 M).
Statistics
All data is presented as mean ± SEM. Bonferonni’s multi-
ple comparison test was performed post hoc to compare 
all measures to one another. The criterion for statistical 
significance was p < 0.05.
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